ReviewFrontiers in pediatrics2023
Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
Review in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.The Journal of clinical endocrinology and metabolism · 2025Article
- Neurophysiological changes associated with dysglycemia in term neonates with neonatal encephalopathy.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025Article
- Investigating brain haemodynamics during hypoglycaemia in very preterm neonates using diffuse optical tomography.medRxiv : the preprint server for health sciences · 2025Article
- Exploring the long-term impacts of neonatal hypoglycemia to determine a safe threshold for glucose concentrations.European journal of pediatrics · 2025Review
- The practical operation and consequences of glucose measurement by pilots with diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Developing a congenital hyperinsulinism prioritized research agenda: a patient-driven international collaborative research network.Frontiers in endocrinology · 2025Article
- Neonatal Hypoglycemia and Neurodevelopmental Outcomes-An Updated Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2024Review
- Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes.Pediatric research · 2024Review
- Agreement between intermittent glucose concentrations and continuous glucose monitoring in at-risk newborns.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- The Utility and Safety of a Continuous Glucose Monitoring System (CGMS) in Asphyxiated Neonates during Therapeutic Hypothermia.Diagnostics (Basel, Switzerland) · 2023Article
- Continuous Glucose Monitoring: A Possible Aid for Detecting Hypoglycemic Events during Insulin Tolerance Tests.Sensors (Basel, Switzerland) · 2023Article
- Continuous Glucose Monitoring in Transient Neonatal Diabetes Mellitus-2 Case Reports and Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The National Institute for Clinical Excellence (NICE) now recommends that continuous glucose monitoring (CGM) be offered to adults and children with diabetes who are at risk from hypoglycaemia. Hypoglycaemia is common in the neonatal period, and is a preventable cause of poor neurodevelopmental outcome, but is CGM helpful in the management of neonates at risk of hypoglycaemia? Neonatal studies have shown that CGM can detect clinically silent hypoglycaemia, which has been associated with reduced executive and visual function in early childhood. Intervention trials have further shown CGM can support the targeting of glucose levels in high-risk extremely preterm neonates. In spite of significant advances in technology, including smaller sensors, better accuracy and factory calibration, further progress and adoption into clinical practice has been limited as current devices are not designed nor have regulatory approval for the specific needs of the newborn. The use of CGM has the potential to support clinical management, and prevention of hypoglycaemia but must be set within its current limitations. The data CGM provides however also provides an important opportunity to improve our understanding of potential risks of hypoglycaemia and the impact of clinical interventions to prevent it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.